Understanding and Mitigating the Cardiometabolic Risks of ADT

Dr Higano explains how the use of ADT in patients with prostat ecancer may impact metabolic and cardiovascular (CV) risk factors, and shares best practices on optimizing risk assessment, mitigation, and monitoring for these factors.

Related Videos
Expert on prostate cancer
Expert on prostate cancer
Expert on prostate cancer
Dr. Jim C. Hu in an interview with Urology Times
Prostate cancer cell dividing | Image Credit: © PRB ARTS - stock.adobe.com
Prostate cancer cells dividing | Image Credit: © PRB ARTS - stock.adobe.com
© 2023 MJH Life Sciences

All rights reserved.